GI Peptides (KPV, Larazotide)
Experimental peptides targeting gut inflammation (KPV) and intestinal permeability (Larazotide)
Quick Answer
GI peptides like KPV and Larazotide target different aspects of gut dysfunction. KPV is a tripeptide derived from alpha-MSH with anti-inflammatory effects, it reduced colitis in animal studies by inhibiting NF-κB signaling. Larazotide is a tight junction regulator that reduces intestinal permeability ("leaky gut") and has shown benefit in celiac disease trials. Both are experimental, with Larazotide further along in clinical development. These represent emerging peptide approaches to gut health beyond BPC-157.
Emerging
New research, promising but early
Safety: These peptides are experimental. Larazotide has completed phase III clinical trials with good safety. KPV has shown anti-inflammatory effects in animal studies. Neither is approved for clinical use.
What Is This?
GI peptides are short amino acid chains that target specific aspects of gut function. Two peptides generating interest for gut health are KPV and Larazotide:
KPV (Lysine-Proline-Valine):
- Tripeptide derived from alpha-melanocyte-stimulating hormone (α-MSH)
- Anti-inflammatory properties
- Transported into gut cells via the PepT1 transporter
- Inhibits inflammatory signaling (NF-κB, MAPK pathways)
- Research shows oral KPV reduced colitis severity in mouse models
- Synthetic eight-amino-acid peptide
- Derived from bacterial enterotoxin (but modified to be non-toxic)
- Regulates tight junctions between intestinal cells
- Reduces intestinal permeability ("leaky gut")
- Phase III clinical trials for celiac disease
- First-in-class tight junction regulator
How It Works
KPV Mechanism: KPV works through the PepT1 transporter, which becomes upregulated in inflamed intestinal tissue. This means inflamed gut tissue actually takes up MORE of the peptide, a natural targeting mechanism.
Once inside cells, KPV inhibits key inflammatory pathways:
- Blocks NF-κB activation (master inflammatory regulator)
- Inhibits MAPK signaling
- Reduces pro-inflammatory cytokine production (TNF-α, IL-1β)
- Decreases neutrophil recruitment to inflamed tissue
Larazotide Mechanism: Intestinal permeability ("leaky gut") occurs when tight junctions between gut cells become disrupted. This allows food antigens, bacteria, and toxins to pass through, triggering immune responses.
Larazotide works as a zonulin antagonist. Zonulin is a protein that opens tight junctions. In conditions like celiac disease, gliadin (gluten protein) triggers zonulin release, increasing permeability.
Larazotide:
- Stabilizes tight junction proteins
- Inhibits myosin light chain phosphorylation (which normally opens junctions)
- Promotes tight junction assembly
- Reduces gluten-induced permeability
How to Start
Understand the experimental status
Neither KPV nor Larazotide is approved for clinical use. Larazotide is in late-stage clinical trials for celiac disease but not yet available. KPV is available as a research peptide but has less human data.
Tips:
- •Larazotide may become available if FDA-approved for celiac disease
- •KPV is primarily supported by animal research
- •Consider whether BPC-157 or conventional treatments might be more appropriate first
- •Consult with a practitioner experienced with peptides
Sourcing considerations
If choosing to use these peptides, source quality is critical. KPV is available from research peptide suppliers. Larazotide is harder to obtain as it is still in clinical development.
Tips:
- •Look for third-party purity testing (HPLC)
- •Compounding pharmacies may offer better quality assurance
- •Avoid extremely cheap sources, purity is suspect
- •Some combination products contain multiple gut peptides
Dosing guidance (KPV)
KPV research used various doses in animals. Human equivalent dosing is estimated but not established. Some practitioners suggest starting with low doses (100-250mcg) and assessing tolerance.
Tips:
- •Oral administration is appropriate for gut-specific effects
- •Take on empty stomach for best absorption
- •Start low and increase gradually
- •Monitor for any adverse effects
Combine with foundational interventions
Peptides work best when combined with foundational gut health practices, not as standalone magic bullets. Diet, stress management, and addressing underlying causes remain important.
Tips:
- •Continue anti-inflammatory diet practices
- •Address food sensitivities through elimination diet
- •Manage stress, which directly affects gut permeability
- •Consider combining with other gut-supportive compounds (L-glutamine, probiotics)
What to Expect
Initial period
Based on animal research showing relatively rapid effects, some users may notice early improvements in inflammatory symptoms. Tight junction regulation may take longer to manifest as symptom relief.
Potential improvements
If these peptides are providing benefit, improvements in bloating, food reactions, and inflammatory symptoms may become more apparent.
Assessment
Evaluate whether symptoms have improved. For permeability issues (larazotide mechanism), improvements in food reactivity and systemic inflammation may become noticeable.
Practical Details
Timing
Typically taken orally on empty stomach. Some protocols suggest multiple daily doses for KPV.
Duration
Optimal duration is not established. Clinical trials of larazotide lasted weeks to months. Many users experiment with 4-12 week protocols.
Cost
$50-$200/month
Cost varies significantly by source and quality. Research peptide sources are generally cheaper but quality is uncertain. Compounding pharmacy sources cost more but offer quality assurance.
Risks & Considerations
Potential Risks
- •Limited human safety data, especially for KPV
- •Product quality and purity concerns
- •Unknown long-term effects
- •May delay seeking appropriate medical care
Possible Side Effects
- •Limited data on side effects for KPV in humans
- •Larazotide trials showed safety profile comparable to placebo
- •Theoretical GI upset when starting
Who Should Avoid This
- •Pregnancy or breastfeeding (no safety data)
- •Active malignancy (theoretical concerns)
- •Those with compromised immune systems
- •When appropriate medical workup has not been completed
Key Research
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Gastroenterology, 2008
KPV inhibits inflammatory signaling and reduces pro-inflammatory cytokine secretion even at nanomolar concentrations. Oral administration reduced colitis severity in two mouse models. Effect was mediated through the PepT1 transporter expressed in intestinal and immune cells.
View StudyLarazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial
Gastroenterology, 2015
In 342 celiac patients on gluten-free diets, larazotide 0.5mg three times daily produced a 26% decrease in symptomatic days compared to placebo. Described as "a successful trial of a novel therapeutic agent targeting tight junction regulation."
View StudyLarazotide acetate: a pharmacological peptide approach to tight junction regulation
American Journal of Physiology-Gastrointestinal and Liver Physiology, 2021
Review of larazotide mechanism found it acts as a zonulin antagonist, reducing zonulin-induced increases in intestinal permeability. Stabilizes tight junction proteins and inhibits myosin light chain phosphorylation through ROCK pathway inhibition.
View StudyFrequently Asked Questions
Which peptide should I try first for gut issues?
BPC-157 has the most research for general gut healing. If inflammation is your primary issue, KPV may be worth considering. If you suspect permeability/leaky gut or have celiac disease, larazotide targets that mechanism specifically. Many people combine these with foundational support like L-glutamine.
Can I combine KPV with BPC-157?
Some practitioners and users combine gut peptides, as they work through different mechanisms. KPV targets inflammation, BPC-157 promotes healing and angiogenesis. There is no research on this combination specifically, so it is experimental.
When will larazotide be available?
Larazotide has completed phase III trials for celiac disease and is awaiting FDA decision. If approved, it would be available by prescription. Timeline is uncertain but could be within 1-3 years.
Is KPV the same as alpha-MSH?
KPV is a tripeptide fragment of alpha-MSH. It contains the anti-inflammatory signaling portion without other hormonal effects of the full alpha-MSH molecule. This makes it more targeted for gut inflammation.
Sources
Related Interventions
Disclaimer: This information is for educational purposes only and is not medical advice. Always consult with a qualified healthcare provider before starting any new health practice or supplement. Evidence levels and recommendations can change, this content was last updated December 2025.